Table of Contents
Pharmacokinetic Issues of Flexeril OTC
Pharmacokinetic Studies
Absorption and Bioavailability
Plasma Concentration-Time Profiles
Plasma Protein Binding
Elimination of Cyclobenzaprine
Proposed Metabolic Pathway
Metabolism of Cyclobenzaprine
Elderly vs. Young
Elderly vs. Young
Hepatic Impairment Patients
Hepatic Impairment Patients
Hepatic Impairment Patients
PK Considerations in OTC Switch
PK Considerations in OTC Switch
Future Goal
PPT Slide
Plasma Concentration-Time Profiles
Mean PK Parameters
Mass Balance Study
Urinary Metabolites
Mass Balance Study
Metabolism of Cyclobenzaprine
Gender
Gender
Elderly vs. Young
Elderly vs. Young
Elderly vs. Young
Elderly - Mean PK Parameters
Elderly - Mean PK Parameters
Child-Pugh Classification
Hepatic Patients - PK Parameters
Effect of Hepatic Impairment - Male vs. Female
Km Values
Ki
|